Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
LTR Pharma Limited ( (AU:LTP) ) has shared an update.
LTR Pharma Limited has received regulatory clearance from the Therapeutic Goods Administration (TGA) for its SPONTAN® Phase II clinical study, marking a significant milestone for the company. This clearance allows the commencement of clinical trials in Australia, focusing on older men, a demographic often underserved by current oral PDE5 therapies. The study will provide valuable insights for physicians treating erectile dysfunction in men aged 65 and over, with patient recruitment expected to begin in the first quarter of 2026.
More about LTR Pharma Limited
LTR Pharma is a commercial-stage pharmaceutical company focused on delivering innovative therapies through its proprietary intranasal drug-delivery platform. The company has successfully commercialized rapid-acting treatment technologies in Australia and is expanding its reach in the US and other key markets. LTR’s lead products include SPONTAN® and ROXUS®, fast-acting intranasal sprays for erectile dysfunction, and it is developing OROFLOW® for Oesophageal Motility Disorders. The company aims to enhance quality of life through strategic partnerships and a growing pipeline of patient-centric treatments.
Average Trading Volume: 567,396
Technical Sentiment Signal: Sell
Current Market Cap: A$76.29M
Find detailed analytics on LTP stock on TipRanks’ Stock Analysis page.